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Hemolytic uremic syndrome (HUS) is a potentially life-threatening condition. It often occurs after gastrointestinal infection with E. coli O157:H7, which produces Shiga toxins (Stx) that cause hemolytic anemia,
thrombocytopenia, and renal injury. Stx-mediated changes in endothelial phenotype have been linked to
the pathogenesis of HUS. Here we report our studies investigating Stx-induced changes in gene expression
and their contribution to the pathogenesis of HUS. Stx function by inactivating host ribosomes but can
also alter gene expression at concentrations that minimally affect global protein synthesis. Gene expression profiling of human microvascular endothelium treated with Stx implicated a role for activation of
CXCR4 and CXCR7 by their shared cognate chemokine ligand (stromal cell–derived factor-1 [SDF-1]) in
Stx-mediated pathophysiology. The changes in gene expression required a catalytically active Stx A subunit
and were mediated by enhanced transcription and mRNA stability. Stx also enhanced the association of
CXCR4, CXCR7, and SDF1 mRNAs with ribosomes. In a mouse model of Stx-mediated pathology, we noted
changes in plasma and tissue content of CXCR4, CXCR7, and SDF-1 after Stx exposure. Furthermore, inhibition of the CXCR4/SDF-1 interaction decreased endothelial activation and organ injury and improved
animal survival. Finally, in children infected with E. coli O157:H7, plasma SDF-1 levels were elevated in
individuals who progressed to HUS. Collectively, these data implicate the CXCR4/CXCR7/SDF-1 pathway
in Stx-mediated pathogenesis and suggest novel therapeutic strategies for prevention and/or treatment of
complications associated with E. coli O157:H7 infection.
Introduction
Hemolytic uremic syndrome (HUS) is a dramatic illness characterized by nonimmune hemolytic anemia, thrombocytopenia, and
acute renal failure (1). A major breakthrough in our understanding of this disease occurred 3 decades ago, with the epidemiological association of HUS, hemorrhagic colitis, and stool isolates of
E. coli, specifically serotype O157:H7. Since then, whenever there
are reports of food- or water-source epidemics of virulent E. coli,
the public and governments immediately become engaged, even
more so since children are especially at risk of diarrhea-associated HUS, a leading cause of acquired pediatric acute renal failure.
E. coli O157:H7 produce Shiga toxins (Stx), also known as ShigaConflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J Clin Invest. 2012;122(2):759–776. doi:10.1172/JCI57313.
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like toxins or verotoxins. These protein exotoxins are strongly
implicated in the pathogenesis of this microangiopathy.
Beginning in May 2011, a large outbreak of diarrhea-associated
HUS was documented in deaths in Northern Germany (2, 3). Rather
than the typical enterohemorrhagic (EHEC) E. coli O157:H7, the
serotype for this epidemic was an enteroaggregative (EAEC) E. coli
O104:H4 that had acquired the stx2 gene, presumably via horizontal gene transfer (4, 5). This especially virulent strain was associated with a high incidence of HUS that resulted in over 40 deaths
(2, 3). Sadly, this new epidemic underscores the seminal role that
Stx play in the pathophysiology of diarrhea-associated HUS.
The family of Stx comprises various forms, including Stx1,
Stx1c, Stx2, Stx2c, Stx2d, Stx2e, and Stx2f (6). Stx2 is the variant
associated with more severe human disease (7, 8). It has long been
appreciated that Stx are enzymatic ribosome-inactivating proteins
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that enter cells via binding to globotriaosylceramide (Gb3) (9) and
catalyze the N-glycosidase–mediated removal of a single adenine
residue within the 28S ribosomal RNA of the large 60S ribosome
subunit (10). However, it is becoming increasingly apparent that
Stx can have profound effects on endothelial gene expression and
phenotype at concentrations that have only minimal effects on
new protein synthesis (11). The extent to which Stx-induced phenotypic changes are caused by inhibition of global protein synthesis instead of activation of specific cellular pathways is currently
unclear. We have previously shown that low concentrations of Stx
selectively increase specific mRNA levels in endothelial cells (11).
In these studies, Stx was found to potently increase preproendothelin-1 mRNA, the precursor of the endothelial vasoconstrictor endothelin-1 (ET-1). Moreover, the observed upregulation of
ET-1 was attributed to Stx-induced stabilization of the transcript.
Thus, low levels of Stx may act to modulate gene expression and
endothelial phenotype in HUS.
To gain a greater understanding of Stx biology, we developed
an in vitro model of extremely sensitive human microvascular
endothelial cells (HMVECs) and performed gene expression profiling after Stx treatment. This agnosic approach identified perturbation of the CXCR4/CXCR7/ stromal cell–derived factor-1
(CXCR4/CXCR7/SDF-1) pathway, which consists of 2 G protein–
coupled receptors (CXCR4, CXCR7) and their shared cognate chemokine ligand (SDF-1/CXCL12), as a key target of Stx-induced
changes in mRNA expression. An emerging theme indicates that
decreased and increased activity of the CXCR4/SDF-1 axis is relevant to diseases of the vasculature. For instance, CXCR4 and/or
SDF-1 deficiency have been shown to cause perinatal lethality in
mice, due, in part, to a defective vasculature (12–14). Cxcr4–/– and
Sdf1–/– mice exhibit defective vascular remodeling in the gastrointestinal tract (12, 13) and disorganized glomerular blood vessels in
the kidneys (14). In the latter study, podocyte-derived SDF-1 was
shown to be required for proper patterning of CXCR4+ endothelial
cells. This axis has also been shown to be fundamental in postnatal
angiogenesis and vascular repair (15–18). In contrast, an overactive
CXCR4/SDF-1 pathway has been associated with various forms of
kidney pathology, including glomerulopathies (19–21). For example, podocyte-specific expression of CXCR4 was shown to disrupt
glomerular function (19). Taken together, these findings suggest
that tight regulation of this axis is essential for homeostasis.
Given its central roles in kidney and endothelial biology, the
CXCR4/CXCR7/SDF-1 pathway was of particular interest in our
studies on Stx-mediated pathophysiology. In the studies reported
here, we have defined a mechanism by which Stx affects gene
expression, especially engagement of select target RNAs on ribosomes in Stx-treated cells. In addition, we have developed and
characterized a murine model of pathogenesis and discovered a
key role for this important biological pathway in mediating experimental Stx-induced disease. Finally, the clinical relevance of the
work was addressed. We found elevated levels of SDF-1 in plasma
samples from children who were destined to develop HUS as a
complication of E. coli O157:H7 infection. Taken together, our
data implicate an important role for the CXCR4/CXCR7/SDF-1
pathway in the pathogenesis of HUS.
Results
Low concentrations of Stx affect global metabolism in the microvascular endothelium. To study Stx-mediated pathogenesis of HUS,
we established an in vitro model using primary HMVECs. The
760
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Stx sensitivity of HMVECs isolated from multiple donors was
assessed after 24 hours of exposure to Stx1 or Stx2 (Figure 1A
and Supplemental Figure 1A; supplemental material available
online with this article; doi:10.1172/JCI57313DS1). HMVECs
showed a concentration-dependent inhibition of leucine incorporation into nascent proteins, with decreased levels of protein
synthesis observed at concentrations as low as 10 fM Stx2. The
IC50 for leucine incorporation in HMVECs was 170.9 ± 50.3 fM
Stx2, more than 3 × 105 times less than the IC50 observed for aortic endothelial cells used in previous studies (11). Similar results
were obtained using [3H]methionine incorporation as an alternate
measure of nascent protein synthesis (Supplemental Figure 1B).
Stx2 also inhibited DNA and RNA synthesis, although this inhibition required higher concentrations of toxin (Supplemental Figure 1, C and D). Protein synthesis was also measured in HUVECs,
a classic in vitro endothelial model. Consistent with previous
reports (22, 23), protein synthesis inhibition in this macrovascular
endothelial cell type was shown to be approximately 105 times less
sensitive to Stx (Figure 1A), highlighting important phenotypic
differences, especially sensitivity to Stx, among endothelial cells
cultured from different vascular beds. Global protein synthesis
was unaffected in cells treated with the receptor-binding B subunit alone or a holotoxin containing 2 amino acid substitutions
in the enzymatic A subunit (Figure 1B). Lactate dehydrogenase
(LDH) release by cells treated with Stx2 demonstrated minimal
or no cytotoxicity with 1,000 fM or 10 fM, respectively (Supplemental Figure 1E). Annexin V staining also indicated only minor
apoptosis (1,000 fM, 24 hours), which could be blocked by the
pan-caspase inhibitor, ZVAD (Supplemental Figure 1F).
Stx potently affect microvascular endothelial gene expression. To better understand the role of Stx in pathogenesis, we conducted gene
expression profiling studies on HMVECs treated with Stx2 (10 fM,
24 hours; n = 6). The approach in this study was to focus on a
concentration of Stx2 that had relatively minor effects on overall
protein synthesis. The reasoning behind this approach is twofold.
Because free Stx has never been detected in human blood, it has
been speculated that endothelial cells are exposed to very small
amounts of Stx at any given time. More importantly, at low concentrations of Stx, the majority of the cellular translation machinery is still functional, so changes in mRNA levels are more likely to
correspond to changes in protein levels.
The endothelial gene expression pattern observed was highly gene
specific, as Stx altered expression of only 369 (2.5%) of the 14,500
genes represented on the microarray (Supplemental Table 1).
Of the 369 unique, differentially expressed genes, 318 (86.2%)
were upregulated (Figure 1C), compared with only 51 (13.8%) that
were downregulated. A variety of preprocessing steps yielded comparable findings. Quantitative RT-PCR (qRT-PCR) was used to
independently verify the microarray results for 11 genes, including those that were upregulated and downregulated. In addition
to validating genes that displayed some of the highest absolute
fold changes, we also confirmed increased expression for genes
that were at the user-defined 2-fold threshold used in the statistical analysis of the arrays (Supplemental Figure 2). For example,
ICAM1, predicted to be induced approximately 2 fold by our
microarray analysis, was also confirmed by qRT-PCR.
The top 30 differentially expressed probe sets (based on magnitude of change) are summarized in a heat map (Figure 1D).
Among the most highly induced genes were 2 closely related
chemokine receptors, CXCR4 and CXCR7, which increased 16.5
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disorders (19–21, 26). Less is
currently known about the
biology of CXCR7, although
it has been shown to be important in cardiac development
and biology (27, 28). Since
HUS is a microangiopathic
disorder, at least in humans,
we were interested in further
examining the involvement
of the CXCR4/CXCR7/SDF-1
pathway in Stx pathogenesis.
We independently confirmed
the microarray results using
qRT-PCR and found timeand concentration-dependent
increases in all 3 genes (Figure
2A). These findings were recapitulated in HMVECs treated
with another Stx variant, Stx1
(Figure 2B), which shares
58% identity in amino acid
sequence with Stx2 (29). SDF-1
is the sole known ligand for
CXCR4 to date, while CXCR7
binds to SDF-1 as well as to
interferon-inducible T cell α
chemoattractant (I-TAC) (30).
Although I-TAC was represented by 2 independent probe
sets on the HG-U133A arrays,
its expression was not significantly altered by Stx2 treatment (10 fM, 24 hours), and
Figure 1
these findings were confirmed
Stx have potent effects on endothelial cell metabolism and phenotype. HMVECs or HUVECs were treated
with vehicle (Veh) or the indicated concentrations of (A) Stx2, (B) Stx1 B subunit alone (B) (1,000 fM), or by qRT-PCR (data not shown).
Changes in gene expression
holotoxin with a double mutation in the A subunit (A mut) (1,000 fM) for 24 hours. One hour before harvest,
3
require
a catalytically active Stx
1 μCi [ H]leucine was added to assess de novo protein synthesis. Radioactivity incorporated into TCAprecipitable material was quantitated, and data were normalized to vehicle-treated cells. The mean ± SEM A subunit. Stx consist of penof 14 experiments (HMVECs with Stx2), 5 experiments (HUVECs), or 3 experiments (mutants), triplicate tameric receptor-binding B
determinations, is shown. (C) HMVECs (n = 6 replicates) were treated with Stx2 (10 fM, 24 hours) or vehicle subunits covalently linked
and subjected to Affymetrix GeneChip gene expression profiling. By combining probe sets identified as dif- to an enzymatic A subunit,
ferentially expressed by all preprocessing algorithms and removing redundant probe sets, i.e., probe sets
which depurinates eukaryotic
mapping to the same gene, it was determined that 86.2% of differentially expressed genes (318 out of 369
28S
rRNA and inhibits prounique genes) were upregulated by treatment with Stx. (D) The top 30 differentially expressed probe sets
(based on magnitude of differential expression) were summarized in a heat map with hierarchical clustering. tein synthesis (Figure 1, A and
Processed signal intensities (computed using the mmgMOS preprocessing algorithm) are depicted on a log 2 B, and ref. 10). To determine
scale, with rows representing differentially expressed probe sets and columns representing Stx- or vehicle- the basis for differential gene
treated samples. Note that several probe sets correspond to the same genes.
expression, we tested whether
the B subunit alone was sufficient to upregulate CXCR4,
and 7.1 fold, respectively. In addition, we discovered increased CXCR7, and SDF1. Whereas 24-hour treatment of HMVECs with
expression (2.0 fold) of the common cognate ligand for both of 1,000 fM wild-type Stx2 substantially increased expression of
these receptors, SDF-1. Taken together, these data highlighted a these genes, equimolar concentrations of the Stx1 B subunit, as
CXCR4/CXCR7/SDF-1 pathway that was perturbed by Stx in the expected, had no effect on protein synthesis (Figure 1B) and did
microvascular endothelium.
not change mRNA levels (Figure 2C). This indicated that bindStx alter the CXCR4/CXCR7/SDF-1 axis. In addition to its criti- ing of the toxin to its receptor, Gb3, was not sufficient to induce
cal roles in blood vessel development, CXCR4/SDF-1 signaling expression of these genes. Similarly, when cells were treated with
is important in revascularization of ischemic tissues and mainte- an inactive Stx2 holotoxin mutant containing 2 amino acid subnance of the vasculature (16, 18, 24, 25). A disrupted CXCR4/SDF-1 stitutions within the A subunit (E166Q, R169L) (31, 32), mRNA
axis has also been described in a variety of thrombotic and renal levels were not changed (Figure 2C). Taken together, these studies
The Journal of Clinical Investigation
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Figure 2
Stx activates the CXCR4/CXCR7/SDF-1 pathway
in microvascular endothelium by a mechanism
requiring enzymatic activity of the Stx A subunit.
HMVECs were treated with the indicated concentrations of (A) Stx2 or (B) Stx1 for 6 or 24 hours,
and mRNA levels were quantitated by qRT-PCR.
(C) HMVECs were treated with 1,000 fM wild-type
Stx2 (WT), Stx1 B subunit alone, or Stx2 holotoxin consisting of a mutant A subunit and wild-type
B subunit (A mut). mRNA levels were measured
by qRT-PCR. In all cases, data are normalized for GAPDH and 18S and are shown relative to vehicle-treated cells. Similar trends were
observed whether or not data were normalized
to housekeeping genes. Basal levels of CXCR4,
CXCR7, and SDF1 were 1.53 ± 0.43 × 10 4,
7.40 ± 2.20 × 104, and 2.21 ± 0.69 × 104 copies/
μg of input RNA, respectively. The mean ± SEM
of at least 4 independent experiments is shown.
*P < 0.05 vs. vehicle-treated cells.

indicate that the A subunit must be present and catalytically active
to elicit changes in gene expression.
Stx increases steady-state CXCR4 mRNA by transcriptional as well as
posttranscriptional mechanisms. We and others have shown that Stx
increases levels of mRNAs via transcript stabilization, without transcriptional activation (11, 33–35). These observations compel study
of the role of ribosome and mRNA interactions, especially because
related ribosome-inactivating proteins, such as ricin, have comparable effects on gene expression (11). Like ET1, CXCR4 is a shortlived mRNA with a half-life of 1.18 ± 0.09 hours (Figure 3A). Upon
Stx treatment (1,000 fM, 20 hours), its mRNA half-life increased
to 19.2 ± 7.8 hours (Figure 3A). Although we observed a dramatic
posttranscriptional effect, a role for transcription could not be
excluded. We therefore assessed the levels of RNA polymerase II
associated with the CXCR4 promoter in Stx-treated HMVECs by
ChIP. A concentration- and time-dependent increase in polymerase
II recruited to the CXCR4 locus was observed (Figure 3B). Hence,
even though transcriptional effects were modest relative to those
of posttranscriptional mechanisms, a combination of both nuclear events and posttranscriptional mechanisms contributed to the
marked mRNA induction of CXCR4 by Stx. This could explain why
CXCR4 was among the most highly differentially expressed mRNA
transcripts in our microarray studies (Figure 1D).
762
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The CXCR4/CXCR7/SDF-1 pathway is regulated specifically by Stx
through mechanisms distinct from those of other classic endothelial stimuli.
TNF-α is an important proinflammatory cytokine and potent
endothelial cell activator, which has been suggested to mediate many of the in vivo effects of Stx. To determine whether the
CXCR4/CXCR7/SDF-1 pathway responds nonspecifically when
the endothelium is activated, or whether this response is specific to
Stx, HMVECs were treated with TNF-α (10 ng/ml), and mRNA levels were measured using qRT-PCR (Supplemental Figure 3). Similar to that with Stx treatment, TNF-α increased CXCR7 expression,
but, in contrast to that with Stx treatment, CXCR4 and SDF1 levels were dramatically reduced by TNF-α. These data indicate that
Stx-mediated stimulation of the CXCR4/CXCR7/SDF-1 pathway
in microvascular endothelium clearly differs from expression patterns produced by another classic endothelial activator.
An additional, biologically important vascular stimulus is
hypoxia. Similar to the Stx-induced response, hypoxia increased
expression of CXCR4, CXCR7, and SDF1 mRNAs (Figure 3C). However, Stx induced upregulation of all 3 components of the pathway
by 24 hours, while hypoxia increased these receptor messages by
6 hours, followed by a delayed increase in their ligand at 24 hours.
CXCR4 and SDF-1 expression is increased in a variety of hypoxic
tissues and cells, and this pair is a target of HIF (16, 36, 37). CXCR7
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Figure 3
Stx enhances CXCR4 expression by both transcriptional
and posttranscriptional mechanisms. (A) HMVECs treated
with vehicle or 1,000 fM Stx2 for 20 hours were subjected
to transcription arrest with 10 μg/ml actinomycin D, and
RNA was harvested at various times thereafter. Remaining
CXCR4 mRNA was determined using qRT-PCR and normalized to 18S. The mean ± SEM of 3 independent experiments is shown. Half-lives were calculated using exponential regression to be 1.18 ± 0.09 hours in vehicle-treated
cells and 19.2 ± 7.8 hours in Stx-treated cells. (B) HMVECs
were exposed to 1,000 fM Stx2 for 20 hours, followed by
ChIP using anti-RNA polymerase II (Pol II) antibodies. qRTPCR for CXCR4 was then used to determine the amount
of immunoprecipitated DNA (IP DNA). The mean ± SEM of
at least 4 independent experiments is shown. (C) HMVECs
were maintained under normoxic (21% O2) or hypoxic (<1%
O2) conditions for the indicated times. qRT-PCR was used to
determine mRNA levels. Data are normalized for 18S levels
and are shown relative to normoxic cells. The mean ± SEM
of 3 independent experiments is shown. Similar trends were
observed whether or not data are normalized to housekeeping genes. (D) Western blot analyses were performed for
HIF-1α and HIF-2α in HMVECs treated with 10 fM or 1,000
fM Stx for 6 or 24 hours. Lamin A/C was used as a loading
control. Negative control and positive control were normoxic
and hypoxic HMVECs. *P < 0.05 vs. vehicle or normoxia.

has been shown to increase in lung, but not other tissues, during
hypoxia (38). The similarity of the effects of Stx and hypoxia on
the CXCR4/CXCR7/SDF-1 pathway, and our observation that
CXCR4 is partly induced by transcription by Stx, prompted us to
examine the potential involvement of HIF in Stx biology. Neither
HIF-1α nor HIF-2α accumulated in Stx-treated cells as they did
in hypoxic HMVECs (1 % O2, 24 hours) (Figure 3D). Hence, HIF
appears not to have a direct transcriptional effect on this pathway
in the context of Stx, and this discordance suggests that Stx and
hypoxia target the pathway via distinct mechanisms.
Stx enhances association of CXCR4, CXCR7, and SDF-1 transcripts with
cellular polyribosomes. Because Stx in sufficient concentrations inactivates protein synthesis, it was important to address translation
of CXCR4, CXCR7, and SDF-1 in addition to steady-state mRNA
levels. We assessed whether the individual transcripts were being
loaded onto ribosomes for translation by fractionating cellular
ribosomes and their associated RNAs from Stx- and vehicle-treated HMVECs. We also used a synthetic exogenous mRNA transcript
to control for mRNA recovery and first-strand cDNA synthesis
efficiency for rigorous quantification of total cellular RNA and
ribosome fraction RNA content. CXCR4 and CXCR7 transcripts
accumulated in polyribosome fractions (heavier fractions) after
24-hour treatment with 10 fM and 1,000 fM Stx, compared with
those in vehicle-treated cells (Figure 4, A and B). The most dramatic effect was the increase in CXCR4 mRNA associated with
polyribosomes after addition of 10 fM Stx for 24 hours. This effect
was also evident for both CXCR4 and SDF1. Importantly, there was
The Journal of Clinical Investigation

increased abundance of these transcripts in the polyribosome fractions after treatment with only 10 fM Stx for 24 hours, a concentration at which there is only minimal inhibition of global protein
synthesis (Figure 1A). A key finding is that, even in the absence of
a significant increase in total levels of CXCR4 (1.00-fold change
vs. vehicle) and CXCR7 (2.06-fold change vs. vehicle) mRNA after
6-hour treatment with 1,000 fM Stx (Supplemental Figure 4, B and
4C), there was increased association of these transcripts with the
polyribosome fractions (Figure 4, A and B), suggesting increased
translational efficiency for these particular transcripts. Increased
endothelial cell surface expression of CXCR4 was also observed
by flow cytometry (Supplemental Figure 4A). The observed translational effects of Stx on SDF1 were less pronounced than those
on the SDF-1 receptors (Figure 4C) but were consistent with a
previous report of enhanced SDF-1 release from microvascular
endothelial cells exposed to Stx (39). The translational changes
observed for these Stx target genes are specific and clearly different
from other genes, such as cyclophilin A, which appears to fall off
the ribosomes in the presence of only 10 fM Stx (Figure 4D). These
findings indicate that Stx, a bacterial derived exotoxin that catalytically modifies the 28S ribosomal RNA of the large 60S ribosome
subunit, has transcript-specific effects on the functional interaction between mRNA transcripts and the translating ribosome.
Functional role of the CXCR4/CXCR7/SDF-1 pathway in Stx-mediated endothelial injury. To explore the involvement of an activated
CXCR4/CXCR7/SDF-1 pathway in Stx-mediated endothelial
injury, we examined endothelial monolayer integrity using in
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Figure 4
Stx-treated cells exhibit increased CXCR4, CXCR7, and SDF1 transcripts associated with cellular polyribosomes. HMVECs were treated with
vehicle or the indicated concentrations of Stx for 6 or 24 hours. Cellular ribosomes were fractionated based on density into 20 fractions, and RNA
was purified from each fraction. mRNA levels were quantitated by qRT-PCR, normalized for luciferase mRNA, and shown relative to vehicle
fraction no. 1. 80S refers to 80S ribosome. (A) CXCR4, (B) CXCR7, (C) SDF1, and (D) cyclophilin A. A representative experiment is shown.

vitro permeability assays. Dextran leak and reduced electrical resistance were evident across monolayers treated with Stx (Figure 5A).
As previously shown (40), SDF-1α induces modest increases in
endothelial permeability (Figure 5B). Inhibition of SDF-1/CXCR4
signaling using the CXCR4 antagonist AMD3100/plerixafor
reduced permeability of Stx-treated HMVECs (1,000 fM Stx, 24
hours, n = 3; Figure 5C), thus implicating a role for this pathway in
Stx-mediated endothelial damage.
764
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Stx causes kidney dysfunction in an animal model of pathogenesis. Based
on our in vitro findings, we hypothesized that the CXCR4/CXCR7/
SDF-1 pathway plays a role in Stx-mediated pathogenesis in vivo.
To test this hypothesis, we established and characterized a mouse
model of Stx exposure. Importantly, murine in vivo Stx models
imperfectly recapitulate human HUS. Motto et al. have previously
developed mice deficient in Adamts13, the vWF protease (41). When
Adamts13 was ablated via gene targeting in the widely used inbred
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Figure 5
Functional effects of Stx and the CXCR4/CXCR7/SDF-1 axis on
endothelial permeability. (A) Confluent endothelial monolayers were
grown on transwell filters and treated with the indicated concentrations
of Stx. Stx treatment causes increased dextran leak and decreased
electrical resistance across the monolayer. The mean ± SEM of at least
3 independent experiments is shown. (B) Treatment of HMVECs with
SDF-1 (50 ng/ml, 5 hours) induces dextran leak. The mean ± SEM of
at least 3 independent experiments is shown. (C) Stx-induced HMVEC
permeability is decreased by treatment of AMD3100/plerixafor. A representative experiment of 3 is shown (mean ± SD). *P < 0.05, **P < 0.001
vs. vehicle-treated cells.

lab strain, C57BL/6, no phenotype was observed; however, knockout of this gene in the wild-derived Mus musculus castaneus (CAST/
Ei) strain rendered these mice extremely susceptible to Stx-induced
thrombotic microangiopathy. It was demonstrated that C57BL/6
mice express a truncated form of ADAMTS13 due to an insertional
element within the genetic locus and are already hypomorphic for
this protease (42). Interestingly, however, these mice do not develop overt thrombotic microangiopathy, and genetic modifiers that
protect these inbred strains from such diseases have been mapped
(41, 43). Consistent with this, castaneus mice are naturally more
susceptible to thrombotic diseases. For these reasons, we opted to
use CAST/Ei mice for our in vivo studies. Male and female CAST/
Ei mice received a single i.v. injection of various concentrations of
purified Stx2, and survival was monitored for a period of 10 days.
While both Stx1 and Stx2 affected the CXCR4/CXCR7/SDF-1
pathway, our studies focused specifically on Stx2, as this is the
isoform associated with the most severe forms of human disease
(7, 8). As expected, increasing concentrations of Stx resulted in
increased mortality, with a LD50 approximating 2,400 pg/g. In contrast, we noted that neither the Stx2 A subunit mutant (10 times
the molar LD50) nor the Stx1 B subunit alone (50 times the LD50)
were lethal over a 10-day observation interval (Figure 6A). Of note,
animals treated with wild-type Stx2 exhibited significant weight
The Journal of Clinical Investigation

loss (86.1% ± 1.9% of original weight at day 0; mean ± SEM; P < 0.05
vs. weight at day 0) within 4 days of challenge.
Numerous measures used to evaluate kidney function were
indicative of renal impairment. Fluorescence microangiography
(fluorescent microbead size averaging 0.02 m) showed normal
microvascular architecture within the renal cortex and medulla in
control animals and those treated with Stx for 24 hours (Figure
6B). However, 4 days after Stx injection, cortical perfusion of the
functional vasculature was severely affected, with some mice demonstrating marked changes in glomerular microperfusion (Figure
6B). At the same time, blood creatinine and urea were increased in
Stx-treated animals (Figure 6, C and D). Decreased bicarbonate levels were also observed (Figure 6E). Urinalysis provided further evidence of kidney dysfunction. Urine albumin/creatinine ratios were
significantly higher in Stx-treated animals (Figure 6F) as a result
of significantly lower urine creatinine (Figure 6G) and elevated
albumin leak (Figure 6H). Additionally, mice injected i.v. with
Evans Blue dye, which binds to albumin and serves as a marker
of albumin leak from the vasculature (44), showed release of Evans
Blue/albumin complexes into the urine (Figure 6I). Consistent
with these parameters of disruption of the glomerular permselectivity barrier by Stx, transmission electron microscopic examination of the glomerular microvasculature demonstrated partial
effacement of podocyte foot processes and glomerular endothelial
cell ultrastructural alterations, specifically swelling and vacuolization of the endothelial cells (Figure 6J). The fall in urine creatinine
concentrations, together with the observed elevated plasma creatinine levels, are indicative of Stx-induced acute renal failure in this
mouse model. Animals injected with either mutant form of the
toxin showed blood creatinine and urea levels within the normal
range for this strain (data not shown).
Effects of Stx on hematology and gastrointestinal biology. Thrombocytopenia and hemolytic anemia are prominent pathophysiological features of HUS in patients. The majority of previously
described mouse models do not report anemia, and development
of thrombocytopenia in one model was attributed to cotreatment
with endotoxin (45). Hematologic analysis in our model showed a
modest but significant decrease in hematocrit levels by 24 hours
after Stx injection, which then increased to basal levels by day 4
(Figure 7A). As we previously noted (41) in the outbred CAST/Ei
strain, fragmented red blood cells were not pronounced in peripheral blood smears (data not shown). Platelet levels were not significantly altered by 24 hours after toxin injection; however, they were
substantially increased above basal levels by day 4 (Figure 7B), as in
mice that do not develop thrombocytopenia following Stx (41).
E. coli O157:H7 cause bloody diarrhea and gut injury that normally precedes HUS. Previous studies have demonstrated expression of Gb3 on human gut epithelial cells (46). Additionally, Stx
has previously been shown to induce cecal or colonic hemorrhagic
lesions in rabbits (47), and both purified Stx and culture filtrate
from O157:H7 produced hemorrhagic lesions in a rat model (48).
Purified Stx damages the stomach and intestinal microvasculature,
causing microinfarctions and both intramucosal and lumenal
hemorrhagic lesions, including frank intraluminal blood content
with upper gastrointestinal hemorrhage, in approximately 60% of
treated mice (Figure 7, C–E).
Stx regulation of the CXCR4/CXCR7/SDF-1 pathway in vivo. To determine whether Stx alters the CXCR4/CXCR7/SDF-1 axis in vivo,
mice were injected with Stx, and expression of these messages was
surveyed across tissues by in situ cRNA hybridization (Figure 8A
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Figure 6
Stx challenge causes impaired renal function and mortality in vivo. (A) CAST/Ei mice were injected i.v. with wild-type Stx2 (3,125 pg/g), Stx2
A subunit mutant (10 times LD50), or Stx1 B subunit (50 times LD50), and survival was monitored for 10 days. (B) Mice were injected with Stx2
(2,400 pg/g) and, at the indicated times, animals were perfused with fluorescent microbeads. A representative confocal image of a 100-μm section is shown (original magnification, ×5). Plasma collected from Stx-treated animals shows elevated (C) creatinine and (D) urea and reduced
(E) bicarbonate levels by 4 days after Stx injection. Mice injected with Stx had (F) significantly higher urine albumin/creatinine ratios by 4 days
after Stx injection, (G) lower urine creatinine, and (H) slightly elevated urine albumin. Horizontal bars indicate the median values, boxes indicate
25th to 75th percentiles, and whiskers indicate the minimum and maximum values. (I) Mice injected with Stx or PBS were injected i.v. with 0.1%
Evans Blue dye. Urine samples were collected 1 hour later, and the amount of dye leak was measured spectrophotometrically. (J) Transmission
electron micrographs of glomeruli from control and Stx-treated animals. *P < 0.05, **P < 0.001 vs. day 0 or PBS control.

and Supplemental Figure 6). Consistent with previous studies,
CXCR4 and SDF-1 were highly expressed in the bone marrow
(Supplemental Figure 5), and CXCR7 was expressed in the hearts
of control animals (Supplemental Figure 6). Perturbation of the
pathway at the mRNA level was evident as early as 24 hours after
Stx injection. In particular, CXCR4 expression was increased in
the thymus (Supplemental Figure 6). In contrast, CXCR7 levels
decreased in cardiac tissue by 24 hours after Stx and remained
766
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low at day 4 (Supplemental Figure 6 and data not shown). In situ
hybridization revealed increases in SDF1 mRNA levels in the kidney
and liver by 1 day after toxin treatment (Figure 8A and Supplemental Figure 6), and immunohistochemistry demonstrated increased
SDF-1 protein in the kidney of toxin-treated animals (Figure 8, A
and B). A significant increase in the secreted SDF-1 peptide was
observed in the blood of treated animals by day 4 (median, 2.1 ng/
ml; interquartile range [IQR], 1.6–2.7 ng/ml) compared with that
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Figure 7
Effects of Stx on animal hematology and gastrointestinal biology. (A)
CAST/Ei mice were injected i.v. with Stx2 (2,400 pg/g) on day 0. Blood
samples were taken via saphenous vein at the indicated times. (A)
Hematocrit (HCT) and (B) platelet levels are shown (n = 13 per time
point). (C–E) Approximately 60% of mice develop gastrointestinal
hemorrhage. (C) Gross images of stomach and small intestine from
PBS- and Stx-treated mice. (D) H&E staining shows intraluminal hemorrhage (original magnification, ×50) and (E) intramucosal hemorrhage
(arrows; original magnification, ×100). **P < 0.001.

at day 0 (median, 1.1 ng/ml; IQR, 0.6–1.7 ng/ml) (Figure 8C). It is
possible that decreased expression of CXCR7, which is a scavenging receptor (49, 50), contributed to increased blood levels. It is of
great interest that our in vitro mechanistic studies demonstrated
enhanced translation of the mRNA transcripts for CXCR4, CXCR7,
SDF1 after Stx treatment.
CXCR4 inhibition improves animal survival. Given the multifaceted
nature of the CXCR4/CXCR7/SDF-1 pathway, from proangiogenic functions for tissue repair (12, 13, 51) to its pathological roles
in renal disease and inflammation (19–21), we examined its role in
Stx pathogenesis in our in vivo model. We determined the effects
of the CXCR4 antagonist, AMD3100/plerixafor, which is currently
approved for stem cell mobilization in non-Hodgkin’s lymphoma
and multiple myeloma and represents an attractive option avenue
for patients (52). In conjunction with AMD3100/plerixafor administration, animals received 200–300 μl saline. We chose to replace
fluids, because animals treated with Stx lost weight compared with
untreated animals, and their hematocrit levels increased significantly between days 1 and 4 after Stx injection (Figure 7A). In addition, we observed albumin leak from the microvasculature in the
kidney (Figure 6, G and H). Administration of AMD3100/plerixafor beginning 1 day after Stx challenge improved animal survival
over the course of 10 days (Figure 9A). Survival between days 0 and
5 was identical in both the AMD3100/plerixafor and PBS groups,
with 57.7% survival (15 out of 26 mice in each group). Beyond day 5,

animal survival in the group receiving AMD3100/plerixafor
improved significantly compared with that in the group receiving
PBS (P < 0.05). 42.3% of mice receiving AMD3100/plerixafor survived to day 10, compared with only 23.1% of mice receiving PBS
control injections. These data suggest a key role for the CXCR4/
CXCR7/SDF-1 pathway in Stx pathogenesis and demonstrate that
AMD3100/plerixafor treatment after Stx exposure enhances survival of Stx-treated animals.
Kidney function was also restored in part after AMD3100/
plerixafor treatment, as demonstrated by reductions in both blood
creatinine and urea levels (Figure 9, B and C). Because common
inbred lab mouse strains (45) and the wild-derived castaneus strain
described here do not naturally develop remarkable anemia or
thrombocytopenia when treated with purified Stx, we evaluated
the effects of AMD3100/plerixafor on hematologic parameters
in an Adamts13-deficient castaneus mouse model of thrombotic
microangiopathy described elsewhere (41). Nolasco et al. have
shown that high concentrations of Stx can induce ultra-large vWF
multimer secretion from endothelial cells in culture and delayed
multimer cleavage by ADAMTS13, which, the authors propose,

Figure 8
Stx challenge causes dysregulation of SDF-1 in vivo. (A) SDF-1 in
situ hybridization and immunohistochemistry demonstrate increased
SDF-1 production in the renal cortical tubules (original magnification, ×160). (B) The number of tubules staining positive for SDF-1 by
immunohistochemistry were quantified in 6 nonoverlapping cortical
fields (magnification, ×100). (C) Animals were injected with Stx2 (2,400
pg/g) on day 0, and SDF-1α levels were measured in blood plasma
at the indicated times. Horizontal bars indicate the mean, and each
symbol represents an individual animal. *P < 0.01.
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Figure 9
Blockade of CXCR4/SDF-1 interaction by AMD3100 improves renal
function and promotes animal survival. (A) CAST/Ei mice were injected
with Stx2 (2,400 pg/g) on day 0, followed by daily administration of
AMD3100 (10 μg/g) or an equal volume of PBS beginning 1 day after
Stx. Survival was monitored for 10 days (n = 26 per treatment group).
(B and C) CAST/Ei mice were injected with Stx2 (625 pg/g) on day 0,
followed by daily injections of AMD3100 (10 μg/g) or an equivalent
volume of PBS vehicle. Plasma was collected 4 days after Stx injection and analyzed for (B) creatinine and (C) urea (n = 10–26 animals
per group). Horizontal bars indicate the median values, boxes indicate 25th to 75th percentiles, and whiskers indicate the minimum and
maximum values. *P < 0.05.

leads to enhanced platelet aggregation (53). As previously reported
(41), Adamts13–/– mice treated with Stx developed features consistent with thrombotic microangiopathy, including hemolytic
anemia, with red blood cell fragments and marked reticulocytosis
evident in a peripheral blood smear (Figure 10A), and thrombocytopenia (Figure 10B). Importantly, platelet counts were restored
to normal levels with AMD3100/plerixafor treatment, while saline
administration alone had no effect (Figure 10B). Despite the effect
on platelets, no beneficial effect of the drug was observed with
respect to hematocrit levels (data not shown). To further investigate the mechanism by which this may occur, platelet adhesion
to endothelial cells under fluid flow conditions was measured in
vitro after Stx treatment in the presence and absence of AMD3100/
plerixafor. Toxin-treated endothelial cells exhibited enhanced
platelet adhesion, and inhibition of CXCR4/SDF-1 interaction
significantly reduced platelet strings attached to the endothelial
monolayer (Figure 10, C and D). Other thrombotic abnormalities
observed in HMVECs include increased tissue factor (Tf) (Supplemental Figure 7, A and B) and decreased tissue factor pathway
inhibitor (TFPI) mRNA, protein levels, and biochemical activity
(Supplemental Figure 7, C and D).
SDF-1 levels in patients with gastrointestinal E. coli O157:H7 infection.
To examine whether the CXCR4/CXCR7/SDF-1 axis is altered in
patients with Stx-induced disease, SDF-1 levels were measured in
plasma collected from children younger than 10 years of age with
documented gastrointestinal E. coli O157:H7 infection (54, 55). The
samples were obtained after a similar numbers of days of illness
in 2 groups of children with infection: those with uncomplicated
infection and those in whom HUS subsequently developed. The
hematocrit, platelet count, and serum creatinine concentration
were normal and similar in these 2 groups, as described previously
(55). Thus, hemolysis, quantitative platelet abnormalities, and
renal insufficiency had yet to evolve in the children in whom HUS
subsequently developed. Circulating SDF-1 levels were compared
in children whose infection resolved without further complication
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and in those children who subsequently developed HUS (Figure
11A). Despite the absence of clinically evident microangiopathic
changes or renal insufficiency, the children in whom HUS subsequently developed had a 4-fold increase in median plasma levels of
SDF-1 in the days preceding onset of HUS (median, 94.2 pg/ml,
IQR, 79.3–181.6 pg/ml vs. median, 23.0 pg/ml, IQR, 7.3–69.46 pg/
ml in individuals who were later diagnosed with the disease compared with children with uncomplicated infection, respectively).
Median SDF-1 levels during HUS (median, 62.1 pg/ml; IQR,
33.69–242.2 pg/ml) remained significantly higher compared with
those in individuals with uncomplicated infection. Importantly,
the observed increases in blood SDF-1 levels preceded development
of HUS, suggesting that aberrant regulation of the pathway, either
as a cause or a consequence of endothelial injury, contributes to
progression of the disease. Serial measurements were available for
some patients and showed that SDF-1 levels peaked prior to development of HUS and subsequently decreased (Figure 11B).
Discussion
Stx-mediated HUS is a clinically important microangiopathy that
may follow infection with enterohemorrhagic E. coli, particularly
serotype O157:H7 and the newer O104:H4 enteroaggregative
strain, which has acquired Stx expression. We have established
an in vitro system to study Stx-mediated injury to cells that are
relevant to Stx-mediated HUS and demonstrated the importance
of the CXCR4/CXCR7/SDF-1 axis in eukaryotic injury. An understanding of the effects of Stx on its target vascular cells is critical
to development of efficient intervention strategies. To this end,
we established an in vitro model using primary microvascular
endothelial cells. In many studies to date, HUVECs have been the
endothelial model of choice to study effects of Stx, despite the fact
that they express quantitatively less of the toxin receptor (Gb3) on
their surface and, therefore, exhibit less sensitivity to the toxin (22,
23). Moreover, published reports have shown fundamental differences in the gene expression patterns of endothelial cells isolated
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Figure 10
Blockade of CXCR4/SDF-1 interaction by AMD3100 restores platelet levels in vivo and inhibits platelet adhesion to endothelial cells under flow
conditions in vitro. (A) Blood smears from Adamts13–/– mice injected with Stx2 (625 pg/g) show evidence of red blood cell fragments 4 days after
Stx exposure, with high numbers of reticulocytes (original magnification, ×150). (B) Adamts13–/– mice were injected with Stx2 (625 pg/g) on day 0,
followed by daily injections of AMD3100 (10 μg/g) or PBS. Blood was analyzed for platelet levels prior to Stx injection and again at day 4 after toxin
injection in both groups (n = 9–21 animals per group). *P < 0.05 vs. control animals that received neither Stx nor AMD3100. (C) HMVECs were
grown to confluence in microfluidic channels and were either left untreated or were treated with 10 fM Stx2 (24 hours), after which calcein-labeled
platelets were perfused at constant shear rates of 2.5 dyn/cm2 over the endothelial monolayer. Preincubation of HMVECs with AMD3100 (10 μM)
significantly inhibited platelet adhesion. Images are representative of 5 independent experiments (original magnification, ×15). (D) Quantification
of platelet adhesion to endothelial cells. Data are expressed as mean ± SEM from 5 independent experiments. *P < 0.05; **P < 0.01.

from different vascular beds, in particular macrovascular- and
microvascular-derived endothelium (56, 57). The microvascular
localization of Stx pathology therefore emphasizes the relevance of
our microvascular cell model. In addition, the exquisite sensitivity
of microvascular endothelium allowed us to focus specifically on
the effects of Stx, whereas other cells, such as HUVECs, have usually required sensitization with cytokine pretreatment (58, 59).
In the current study, we expanded our previous work, demonstrating that Stx upregulated ET1 mRNA that occurred at Stx
concentrations that had minimal effects on global cellular protein
synthesis (11). Specifically, we now more comprehensively characterized the gene expression profile of HMVECs after treatment with
10 fM Stx2, which produces only approximately 10% inhibition of
protein synthesis. It is interesting that this low concentration of Stx
had such potent and reproducible effects on endothelial phenotype.
Previous expression profiling studies have been performed using
Stx in HUVECs and in vivo (45, 60). We identified many of the same
The Journal of Clinical Investigation

genes in our work; however, modulation of the CXCR4/CXCR7/
SDF-1 pathway was not described in either previous study. This
might be attributable to the cell model used in the former study,
or source of tissue studied, or LPS cotreatment in the latter study.
Interestingly, Guessous et al. observed elevated SDF-1α protein levels in conditioned media from HMVECs treated with Stx (39).
Our in vitro and in vivo data indicate that A subunit activity is
indispensable for disruption of the CXCR4/CXCR7/SDF-1 pathway and for Stx-mediated mortality. First, studies with the mutant
holotoxin and the receptor-binding B subunit demonstrated that
the toxin must possess a functional A subunit in order to regulate
expression of the CXCR4/CXCR7/SDF-1 pathway both in vitro
and in vivo. Second, though our studies do not exclude important
biological roles of the B subunit (61), our in vivo studies using the
B subunit demonstrated 100% animal survival.
Most of the genes whose expression was affected were upreg
ulated. We and others have previously shown that Stx increases
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respectively). Comparison analysis demonstrates that
only select mRNAs are abundantly associated with polyribosomes during Stx exposure. For instance, cyclophilin A
mRNA transcripts exhibited decreased polyribosome
association in Stx-treated endothelial cells. These findings highlight that changes in mRNA levels alone do not
explain the effects and that specific translational regulation must be taken into consideration, especially in the
case of a bacterial toxin that modifies ribosome activity.
Together, these findings suggest the intriguing possibility that low levels of ribosome damage by small quantities of Stx may modulate selected cell signaling pathways
that change ribosome function. Future mechanistic
studies will be needed to gain greater understanding of
Figure 11
how these putative signaling pathways modify the cell’s
Circulating SDF-1 levels in HUS patients. SDF-1 levels were measured in plas- expression profile and phenotype and whether activama samples from individuals infected with E. coli O157:H7. (A) Infected sam- tion of the CXCR4/CXCR7/SDF-1 pathway is common
ples obtained from patients with uncomplicated O157:H7 infection within 4 days
to other ribosome inhibiting proteins.
after the onset of diarrhea (n = 36). Horizontal bars indicate the median values,
To assess the biological relevance of our in vitro findboxes indicate 25th to 75th percentiles, and whiskers indicate the minimum and
maximum values. Pre-HUS, samples collected prior to HUS diagnosis in those ings, we established an in vivo model of Stx toxicity.
individuals who later progressed to HUS (n = 7); HUS, samples collected on the Kidney impairment is evident in this model, but hemoday of HUS diagnosis (n = 22). *P < 0.05. (B) SDF-1 levels over the course of concentration and gastrointestinal vascular damage
E. coli O157:H7–mediated illness. Each line represents 1 patient, and the last also figure prominently. Our studies also implicated the
data point for each patient was obtained on the day of HUS diagnosis.
CXCR4/CXCR7/SDF-1 pathway as a mediator of Stx
pathology in a murine model. The pattern of tissue damage in our mouse model coincided with tissues in which
particular mRNAs by increasing the half-life of the transcript (11, the CXCR4/CXCR7/SDF-1 pathway has previously been demon33–35). We have also observed Stx-induced ET1 and ICAM1 mRNA strated to play critical roles, including the gastrointestinal vascuexpression via transcript stabilization but observed no change in lature (12, 13) and kidneys (14, 19, 20). Interestingly, overexpresnuclear run-off signal (ref. 11 and P.A. Marsden, unpublished sion of CXCR4 or SDF-1 in the glomerulus causes kidney disease
observations). CXCR4, SDF-1, CXCR7, ICAM-1, and ET-1 share and induces proteinuria (19, 20). In our studies, the Stx-induced
commonalities of basal mRNA lability, enhanced association with albuminuria and hemoconcentration were consistent with the
polyribosomes after Stx addition, and stabilization of mRNA tran- observed in vitro endothelial permeability caused by Stx and SDF-1,
scripts after Stx treatment (ref. 11 and our unpublished observa- which was reduced in our in vitro studies by inhibition of the pathtions). It is of great interest, therefore, that CXCR4 transcription way using AMD3100/plerixafor.
is also enhanced by Stx, explaining the marked increases in CXCR4
The aberrant regulation of the complex and biologically impormRNA steady-state levels in Stx-treated HMVECs. However, nucle- tant CXCR4/CXCR7/SDF-1 axis offers new insight into the pathoar events play a smaller part in the overall increase in steady-state genesis of HUS. We acknowledge the limitation of our studies, in
mRNA, as the slight induction in transcription of CXCR4 with 10 that the murine model is not a robust clinical surrogate for StxfM Stx cannot explain the substantial increase in transcript levels induced HUS. However, advances in understanding the complexiat that concentration.
ties of studying procoagulant pathways in murine models has led
The stark differences between the regulation of the CXCR4/ to the utilization of the outbred CAST/Ei strain, especially when
CXCR7/SDF-1 pathway by Stx and TNF-α suggest that the effect deficient in ADAMTS13. We found that CXCR4 was expressed in
of Stx on endothelial gene regulation is a function of this particular lymphoid organs, and its expression was increased in thymus after
stimulus. CXCR4 and SDF-1 are well-known transcriptional targets Stx exposure. CXCR4 is expressed on a variety of cells, including
of HIF, and as we showed, CXCR7 expression is also augmented in T- and B-thymocytes, and its altered expression here might indiendothelium during hypoxia. Therefore, we considered the possibil- cate an immune response to the toxin. CXCR7 has recently been
ity that Stx is a hypoxia mimetic, possibly via stabilization of HIF-α described as a scavenger receptor that effectively creates and mainsubunits. However, HIF-1α and HIF-2α levels were not affected tains a SDF-1 gradient to support CXCR4 signaling functions (49)
by Stx in HMVECs. Notably, while a subset of hypoxia-regulated by binding SDF-1 and targeting the chemokine for degradation
genes were upregulated in our studies (e.g., VEGF, CXCL1), most did (50). Stx decreases the amount of CXCR7 in the heart and, therenot change (e.g., GLUT1, GLUT3, VEGFR2, TIE2, ANGPTL4). This fore, may increase the amount of free SDF-1 available to signal
dichotomy provides further evidence that Stx acts via a mechanism through CXCR4. Interestingly, while CXCR4/SDF-1 is essential
in a variety of organ systems, CXCR7 is particularly important
distinct from the cellular response to hypoxic stress.
It is key mechanistically that, even without changes in mRNA in proper development and function of the heart (27, 28), and
levels, we observed substantial increases in polyribosome loading CXCR7 present in cardiac tissue has previously been shown to
of specific target transcripts only 6 hours after Stx addition and sequester SDF-1 (50). To date, transgenic overexpression of SDF-1
with very low concentrations of toxin. Moreover, the magnitude of in the heart has not been studied. However, adenovirus-mediated
change in polyribosome association induced by Stx far outweighed overexpression of CXCR4 in cardiac tissue increased SDF-1 levthe changes in mRNA steady-state levels (up to 700 fold vs. 40 fold, els and has been reported to enhance ischemia/reperfusion injury
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(62). The CXCR4/SDF-1 axis is emerging as a key pathway in vascular and other tissue biology, and, thus, a tight balance is necessary to maintain homeostasis. The increase in free SDF-1 might
tip the balance toward CXCR4 signaling on cells expressing the
receptor and contribute to the endothelial dysfunction characteristic of Stx-mediated disease. It is important to note that our in
vivo studies specifically addressed mRNA levels, but as we have
shown in vitro, Stx pathobiology can involve profound changes in
translational efficiency of CXCR4, CXCR7, and SDF1 transcripts,
and this mechanism may also be important in vivo in tissues in
which changes in mRNA levels are not observed.
We addressed the in vivo role of the CXCR4/CXCR7/SDF-1
pathway using the CXCR4 inhibitor AMD3100/plerixafor. This
bicylam compound is a specific antagonist of CXCR4 and does
not appear to inhibit CXCR7 function (63). AMD3100/plerixafor
increases CXCR7 affinity for SDF-1 and functions as a CXCR7
agonist (64). When AMD3100/plerixafor therapy was initiated in
a clinically relevant setting, namely 1 day after Stx challenge, we
observed a beneficial effect on overall survival (Figure 9A). Importantly, CXCR4 inhibition is beneficial to mice already exposed to
the toxin. This has important clinical implications for patients
who visit the hospital only after becoming ill from enteric infection with E. coli O157:H7.
Our data also demonstrate involvement of the CXCR4/CXCR7/
SDF-1 axis in pediatric HUS cases, using plasma from a prospective cohort study of patients with E. coli O157:H7 infection
(54, 55). Children in this phase of infection have prothrombotic
abnormalities, which appear before, and plausibly contribute to,
HUS. We demonstrated marked elevation in blood SDF-1 before
the onset of HUS and azotemia, which could contribute to the
pathogenesis of HUS. SDF-1 has been shown to enhance platelet
activation by low levels of ADP (65) or thrombin (66), leading to
increased aggregation (67) through CXCR4 platelet surface expression. Platelet thrombi are a characteristic feature of HUS. Our data
indicate that Stx augment platelet adhesion in an in vitro flow
model and that AMD3100/plerixafor could inhibit this. Moreover, we found increased and decreased activity of Tf and TFPI,
respectively. Therefore, increased thrombin generation observed
in HUS (55), in combination with increased SDF-1 levels, may
be an important mechanism involved in Stx pathogenesis. The
relationship between increased tissue factor, decreased tissue factor pathway inhibitor, and the effects of thrombin and SDF-1 on
platelet aggregation in the in vivo setting warrants further study.
SDF-1 is also stored in and released by activated platelets (68) and
could exacerbate thrombosis in later stages of disease. Our in vitro
studies demonstrate that AMD3100/plerixafor inhibited formation of platelet strings on the endothelium and may explain why
Adamts13–/– mice receiving the drug displayed normal platelet levels after Stx challenge compared with those of animals that did
not receive the drug.
Taken together, these studies identify Stx-induced activation of
the CXCR4/CXCR7/SDF-1 pathway in vitro and in vivo, demonstrate that this pathway contributes to Stx-mediated pathogenesis,
and present targets which we believe to be novel for therapeutic
intervention. We have found that the median SDF-1 level decreases
in overt HUS. SDF-1 binding to CXCR4 induces permanent internalization of the receptor from the cell surface, so that by the
time HUS ensues, SDF-1 might be cleared from the circulation
by CXCR4 or its other scavenger receptor, CXCR7. Alternatively,
platelet decreases during HUS may account for the fall in median
The Journal of Clinical Investigation

SDF-1 levels. Little overlap exists between the IQRs of SDF-1 measurements in children with uncomplicated infection and those who
later developed HUS. Further studies are therefore warranted to
determine the potential value of plasma SDF-1 level as a predictive
indicator of complications and progression to HUS after infection
with E. coli O157:H7.
In summary, aberrant activation of the CXCR4/CXCR7/SDF-1
pathway in Stx-mediated pathogenesis could provide novel insight
into the molecular mechanisms underlying HUS. Specifically,
CXCR4 inhibition improves renal function and, ultimately, survival in a murine model, and circulating SDF-1 in O157:H7-infected
patients provides complementary data in support of an important
role for this axis in the development of HUS.
Methods
Reagents
[methyl-3H]thymidine (70–90 Ci/mmol), [5,6-3H]uridine (30–50 Ci/mmol),
and l-[3,4,5-3H(N)]leucine (>140 Ci/mmol) were purchased from NENDupont. l-[methyl-3H]methionine (70–85 Ci/mmol) was purchased from
Amersham Biosciences. TNF-α was purchased from Sigma-Aldrich. cDNA
I.M.A.G.E. clones were obtained from ATCC or Invitrogen.

Toxin purification
Wild-type Stx2 holotoxin and Stx2 holotoxin mutant (E167Q and R170L
substitutions in the A subunit) were extracted from recombinant E. coli
strains using a combination of 10 μg/ml lysozyme and 0.1 mg/ml colimycin
in PBS in the presence of 5 mM EDTA and 0.1 g/l PMSF (Sigma-Aldrich).
The extract was cleared by centrifugation, dialyzed against 50 mM acetate
buffer (pH 5), resolved on DEAE Sepharose Fast Flow (Amersham Biosciences), and eluted using a NaCl gradient 0 M to 0.5 M in 50 mM acetate
buffer. Fractions containing Stx were precipitated with 80% ammonium
sulfate, backwashed with 0.8 M ammonium sulfate in 50 mM acetate buffer (pH 5), and diluted to 0.6 M ammonium sulfate in 50 mM acetate buffer (pH 5). Fractions were then loaded on Phenyl Sepharose HP (Amersham
Biosciences), eluted with a decreasing salt gradient, dialyzed against 50 mM
ammonium bicarbonate, lyophilized for storage, and resuspended in PBS.
Stx1 B subunit was purified as previously described (69). Contaminating
lipopolysaccharide was removed by incubating with Affi-Prep polymyxin B
resin overnight (Bio-Rad) at 4°C. Endotoxin content was tested by Limulus
Amebocyte Lysate assay (Associates of Cape Cod Inc.) and determined to be
less than 1 pg endotoxin/μg Stx.

Cell culture
Human dermal neonatal microvascular endothelial cells (HMVECs)
were purchased from Lonza, cultured on 0.2% gelatin, and maintained in
EGM-2MV growth medium (Lonza). Studies were performed on HMVECs
at passages 5 and 6. HUVECs were maintained in M199 (Invitrogen) containing 20% fetal bovine serum (Hyclone), 17 units/ml heparin, and 0.05
mg/ml endothelial mitogen (Biomedical Technologies Inc.), as previously
described (70), and used at passages 3 and 4. Confluent monolayers were
treated with the specified concentrations of Stx or TNF-α (10 ng/ml) for
the indicated times before harvesting. For hypoxia studies, HMVECs were
treated as previously described (71). Total cellular RNA was purified by
CsCl ultracentrifugation, as previously described (72).

Metabolic assays
Metabolite incorporation assays with radiolabeled thymidine, uridine,
and leucine were used to determine the dose-dependent effects of Stx on
global DNA, RNA, and protein synthesis, as described previously (11).
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HMVECs were seeded at a density of 40,000 cells per well in gelatin-coated
24-well plates. Two days after reaching confluence, cells were treated with
varying concentrations of Stx2 for 24 hours. 1 μCi/ml [3H]thymidine,
[ 3H]uridine, [ 3H]leucine, or [3H]methionine was added to each well
1 hour before harvest. After labeling, the cells were quickly washed with
ice-cold PBS to terminate isotope uptake, and incorporated radioactivity
was precipitated with 15% ice-cold TCA for 20 minutes. Cell monolayers
were washed with water and then solubilized with 0.1 M NaOH-0.1% SDS
(w/v). Aliquots from each well were counted using a scintillation counter.
Each experiment was performed on triplicate wells. Data were normalized
to vehicle-treated control wells.

Affymetrix GeneChip expression profiling — sample preparation,
hybridization, and image acquisition
Total cellular RNA (10 μg) from Stx- and vehicle-treated (n = 6 replicates per group) HMVECs was submitted to a core microarray facility
(The Centre for Applied Genomics, Hospital for Sick Children). Sample
preparation, array hybridization, and image acquisition were performed
according to the manufacturer’s technical documentation (Affymetrix).
All samples were hybridized to Affymetrix GeneChip Human Genome
U133A Arrays, housing approximately 14,500 well-characterized human
genes. Raw probe-level intensities were derived from pixel-level data
of the scanned images of hybridized arrays using the manufacturer’s
software (Affymetrix Microarray Suite Version 5.0). Microarray data
were deposited in NCBI’s Gene Expression Omnibus (accession no.
GSE32710; http://www.ncbi.nlm.nih.gov/geo/) in conformity with the
standards put forward by the Microarray Gene Expression Data Society
(http://www.mged.org/).
Quality control metrics. Quality control metrics were assessed using packages made available through the Bioconductor Project implemented in
the R statistical language and environment (version 2.4.0). Quality control
metrics recommended by Affymetrix (average background, scale factor,
percent present, and 3ʹ/5ʹ ratio of control probe sets) were computed using
the simpleaffy package and conformed to the manufacturer’s guidelines.
In addition, the absence of important spatial artifacts, RNA degradation
plots, and the distribution of probe-level intensities across all arrays were
assessed using functions made available in the affy package.
Data preprocessing and determination of differential expression. Raw probelevel intensities were preprocessed using 13 different computational
methods made available as part of the Bioconductor Project (v1.6)
(http://www.bioconductor.org) or as freely available, stand-alone software applications as outlined below. The base affy package was used for
the computation of MAS5.0, RMA, dChip.PM (PM-only), and dChip.PMMM (subtract MM) summary expression measures. Various other Bioconductor packages were used for the computation of GCRMA, PLIER,
VSN, mgMOS, mmgMOS, q.FARMS (quantile normalization), and
l.FARMS (loess normalization) measures. The preferred method of Choe
et al. was also used (73). A stand-alone software application was used for
the computation of the PDNN summary expression measure (PerfectMatch v2.3) (74). All preprocessing methods were used in their default
implementations. Next, a filtering step was performed to remove probe
sets called “absent” across all hybridized arrays (n = 12), as determined by
the Affymetrix Detection Call algorithm implemented in the affy package. Finally, filtered probe set lists were independently submitted to a
test of differential expression, Cyber-T, a regularized t test based on a
Bayesian statistical framework. Probe sets were considered differentially
expressed if they changed by at least 2 fold, with a Bayesian P value of
0.05 and a posterior probability of differential expression (PPDE(<p)) of
0.95. This denotes a global confidence of 95% based on the experimentwide false-positive level.
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Real-time RT-PCR
First-strand cDNA was synthesized from DNase-treated total cellular
RNA, using random hexamers and SuperScript II reverse transcriptase
(Invitrogen), according to the manufacturer’s protocol. SYBR Green and
TaqMan Master Mixes (Applied Biosystems) were used according to manufacturer’s protocols. Quantitative real-time PCR assays were performed
in triplicate using the ABI 7900HT Sequence Detection System (Applied
Biosystems) with the following cycle parameters: 10 minutes at 95°C
and 40 cycles of 10 seconds at 95°C and 1 minute at 60°C. Primers were
designed such that amplified products crossed exon boundaries to exclude
amplification of any remaining genomic DNA in the sample. Serial dilutions of reference plasmids were used to quantitate template copy number.
Results were normalized to the reference genes GAPDH and 18S, both of
which yielded similar results. Primers used in these experiments are listed
in Supplemental Table 2. The cycles at which 1,000 copies of target amplicon passed through the cycle threshold (0.2) were 25.3 ± 0.3, 24.4 ± 0.1,
24.2 ± 0.4 for CXCR4, CXCR7, and SDF-1, respectively.

Polyribosome profiling
Polyribosome profiling was performed as previously described (71). Briefly,
HMVECs were treated with vehicle or 10 fM Stx2 for 6 or 24 hours, washed
in ice-cold phosphate-buffered saline containing 100 μg/ml cycloheximide
(Sigma-Aldrich) and harvested in lysis buffer (100 mM KCl, 5 mM MgCl2,
10 mM HEPES (pH 7.4), 100 μg/ml cycloheximide (Sigma-Aldrich), and
1,000 U/ml RNaseOUT (Invitrogen). Cellular extracts were sheared using
a 27-gauge needle, and the nuclei were pelleted by centrifugation (12,000 g,
4°C, 5 minutes). Cytoplasmic extracts were layered onto 10 ml sucrose
gradients (15%–45%). After ultracentrifugation (SW Ti 41 rotor, 151,260 g,
4°C, 2 hours) (Beckman Coulter), 20 fractions were collected using a programmable density gradient fraction collector (Isco; PerkinElmer Life
Sciences). RNA was extracted from each of the fractions using standard
guanidinium-based protocols and resuspended in 10 μl 0.025 ng exogenously synthesized luciferase. RNA was added to each fraction prior to
RNA purification in order to control for the efficiency of RNA purification
and first-strand reverse transcription. 5 μl RNA from each fraction was
reverse transcribed using SuperScript III (Invitrogen), followed by real-time
PCR to measure mRNA levels in each fraction.

RNA polymerase II ChIP assays
ChIP was performed as previously described (75). Briefly, 5 μg anti–polymerase II antibody (N-20; Santa Cruz Biotechnology Inc.) was added to
each immunoprecipitation reaction. Control immunoprecipitations
containing no antibody were performed in parallel. An input sample was
removed prior to immunoprecipitation. CXCR4 primers (+13 to +124 bp)
were as follows: 5′-CGGCAGCAGGTAGCAAAGTGAC-3′ and 5′-GCAGGTTGAAACTGGACTTACACTG-3′. The number of copies of CXCR4 was
determined in the bound chromatin, a no-antibody control, and a diluted
input sample using serial dilutions of genomic DNA. Immunoprecipitated
DNA was calculated by subtracting the number of copies in the no-antibody control from the bound chromatin and dividing by the input.

Determination of mRNA half-life
To study the effect of Stx on mRNA half-life, confluent HMVECs were left
untreated or were treated with 1,000 fM Stx2 for 20 hours before addition of 10 μg/ml actinomycin D (Sigma-Aldrich) to arrest transcription.
Total cellular RNA was extracted at 0, 5, 15, 30, 60, 120, 180, 270, and 360
minutes after the addition of actinomycin D. Levels of specific transcripts
were determined by real-time RT-PCR using the primers listed above. Data
were normalized to 18S rRNA. Rates of mRNA decay were determined
using exponential regression.
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Western blot

CXCR4 inhibition studies

HMVECs were treated with Stx or vehicle, and total cellular protein collected as described previously (76). 15–20 μg total cellular protein was size
fractionated on NuPAGE Novex 4–12% Bis-Tris gels (Invitrogen) and transferred onto nitrocellulose membranes using the XCell SureLock Mini-Cell
and Xcell II Blot Module (Invitrogen). Mouse monoclonal anti–HIF-1α
(Abcam; 1:200), rabbit polyclonal anti–HIF-2α (Novus Biologicals; 1:800),
and mouse monoclonal anti-Lamin A/C (Santa Cruz Biotechnology Inc.;
1:200) were used as primary antibodies. HRP-linked rabbit anti-mouse
IgG (H & L) and HRP-linked goat anti-rabbit IgG were used as secondary
antibodies. Chemiluminescence signals from immunoreactive bands were
detected using ECL Plus (GE Amersham).

Mice were injected i.v. with 2,400 pg/g Stx2 on day 0 and received daily
i.p. injections of the CXCR4 inhibitor AMD3100/plerixafor (1-1′-[1,4phenylenebis(methylene)-bis(1,4,8,11-tetraazacyclotetradecane]) (SigmaAldrich) at a concentration of 10 μg/g, diluted in PBS. Control mice received
daily injections of PBS. AMD3100/plerixafor administration began either
1 day prior to Stx injection or 1 day after Stx injection. Survival was monitored for a total of 10 days after toxin injection. Alternatively, beginning
1 day after Stx injection, mice received 10 μg anti-CXCR4 (Torrey Pines BioLabs) or rabbit IgG daily via i.p. injection in a volume of 250 μl PBS.

Permeability studies
HMVECs were grown on polyester transwell filters (0.4-mm pore size;
Corning Life Sciences) coated with Attachment Factor (Cascade Biologics) to confluency until the cells achieved a transendothelial electrical
resistance of more than 21 cm2 (measured using Endohm-12, World
Precision Instruments). The cells were treated with the indicated concentrations of Stx for 24 hours or SDF-1α (50 ng/ml) for 5 hours. Fluorescein-conjugated dextran (MW 70 kDa; Invitrogen) was then added
(0.05 mg/ml) to the upper chamber of the transwell. Permeability of
endothelial monolayers was measured by passage of the dextran from
the upper chamber to the lower chamber, as determined by the ratio of
fluorescence in the lower chamber divided by total (upper and lower
chamber) fluorescence. Fluorescence was measured in a spectrofluorometer (Spectramax Gemini EM, Molecular Devices) using an excitation
wavelength of 492 nm and an emission wavelength of 540 nm. In other
experiments, cells were exposed to AMD3100 (10 μM) for 30 minutes
prior to the addition of Stx (1,000 fM, 24 hours). Fresh AMD3100 was
added to the media after 16 hours.

In vivo studies
Inbred, wild-derived CAST/Ei mice were obtained from The Jackson Laboratory. Adamts13–/– mice generated on a castaneus background, as previously described (41), were obtained by heterozygote crosses. All animals
were maintained in pathogen-free facilities at the University of Toronto.
Equal numbers of male and female mice between 8 to 11 weeks of age were
injected i.v. via tail vein injection with the indicated concentrations of Stx2,
Stx1 B subunit (12 ng/g body weight), or Stx2 holotoxin A subunit mutant
(24 ng/g body weight) diluted in PBS, such that injection volumes were
10 μl/g body weight. Control mice received an injection of PBS.

Blood analysis
For hematology analysis, daily blood samples were collected in EDTAcoated tubes via saphenous vein. Alternatively, animals were anesthetized
with isoflurane and exsanguinated by cardiac puncture. Blood was analyzed using a Coulter AcT diff Analyzer (Coulter Corporation). For plasma
biochemistry measurements, blood was collected in heparinized tubes and
centrifuged at 13,000 g for 5 minutes, and plasma was then stored at –80°C
until subsequent analysis.

Urine studies
Urine was collected passively from CAST/Ei mice at various times after
Stx injection. Creatinine levels were quantitated using an alkaline picrate method, and albumin levels were quantitated using an indirect competitive ELISA (Exocell Inc.). Alternatively, animals treated with vehicle
or Stx (2,400 pg/g) for 4 days were injected i.v. with 100 μl 0.1% Evans
Blue dye. One hour after injection, urine samples were collected, and the
OD620 was determined.
The Journal of Clinical Investigation

In situ cRNA hybridization
CAST/Ei mice were injected with Stx2 (2,400 pg/g) or an equivalent volume
of PBS and euthanized at days 1 or 4. Animals were euthanized with CO2,
and OCT was administered by oral gavage to distend the gastrointestinal
tract. After being shaved completely, the animals were frozen in isopentane
and stored at –80°C. 10-μm sections were fixed, hybridized, and washed as
described previously (77). Slides were then dehydrated, exposed to Kodak
BioMaxMR x-ray film, emulsion dipped in Kodak NTB nuclear track emulsion, and exposed in light-tight boxes at 4°C for 12 days for CXCR4 and
CXCR7 and 14 days for SDF-1. A 776-nt probe within exon 2 was used to
detect CXCR4, a 714-nt probe representing exon 2 and a portion of the
3′-UTR was used to detect CXCR7, and a 307-nt probe, including a portion of the 5′-UTR in addition to ORF sequence, was used to detect SDF-1.
The probe used to detect SDF-1 was designed in a region common to all
known murine isoforms. Control sense cRNA probes were used to detect
background levels of hybridization signals.

Immunohistochemistry
Immunohistochemistry was performed with a mouse monoclonal antihuman/mouse SDF-1 antibody (clone 79018) (R&D Systems) at a dilution
of 10 μg/ml, as previously described (78). After incubation with the appropriate HRP-conjugated secondary antibody, sections were labeled with Liquid
Diaminobenzidine and Substrate Chromogen System (DakoCytomation),
before counterstaining in Mayer’s hematoxylin. Positively stained tubules
were counted in 6 nonoverlapping cortical fields at ×100 magnification.

Apoptosis and cytotoxicity assays
HMVECs were treated with 1,000 fM Stx2 for 24 hours. Where indicated,
cells were pretreated with 20 μM ZVAD-FMK or vehicle for 1 hour before
addition of toxin. Apoptosis was assessed by flow cytometry using the
Annexin V-FITC Apoptosis Kit I, per the manufacturer’s instructions (BD
Pharmingen). To determine cytotoxicity, cells were treated with Stx2 for 24
hours, and LDH release was measured using the CytoTox96 Non-Radioactive
Cytotoxicity Assay according to the manufacturer’s instructions (Promega).

Platelet-endothelial adhesion studies
HMVECs were grown to confluence in gelatin-coated channels of the Bioflux
microfluidic system (Fluxion Biosciences) and either left untreated or treated
with 10 fM Stx2 for 24 hours. When AMD3100 was used, it was added 30
minutes prior to addition of platelets at a concentration of 10 μM. Whole
blood samples were collected from healthy donors into acid citrate dextrose
and centrifuged at 160 g for 15 minutes to obtain platelet-rich plasma (PRP).
The PRP was centrifuged at 800 g for 10 minutes and washed twice with
PBS (pH 6.3). The platelet pellet was resuspended in HEPES-Tyrode’s buffer
(136 mM NaCl, 2.7 mM KCl, 0.42 mM NaH2PO4, 19 mM NaHCO3, 0.35
mM Na2HPO4, 5.5 mM glucose, 1 mM CaCl2, 1 mM MgCl2, 10 mM HEPES,
pH 7.2). Calcein-labeled platelets (2 × 107/ml) were perfused through the
channels at constant shear rates of 2.5 dyn/cm2 for up to 10 minutes. Images
were acquired using a Nikon Eclipse Ti inverted confocal microscope while
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the platelets were still under flow, and the fluorescent intensity of adhered
platelets was quantified using the Bioflux 200 analysis software.

Fluorescence microangiography

CAST/Ei mice were injected with Stx2 (2,400 pg/g) and euthanized at various times thereafter. Blood was collected by cardiac puncture into EDTAcoated tubes and centrifuged to collect plasma. SDF-1α levels were quantified by ELISA (R&D Systems). The mean minimal detectable dose for
the assay was 0.044 ng/ml.

Kidney microvascular architecture was assessed in CAST/Ei mice injected
with PBS or Stx2 (2,400 pg/g) using a fluorescence microangiography
technique, essentially as described previously (79). In brief, animals were
anesthetized with inhaled isoflurane 2.5%. The abdominal aorta was cannulated with a 26 G plastic catheter with the tip advanced to a point just
distal to the origins of the renal arteries. Whole-body perfusion/exsanguination commenced at 100–120 mmHg via the abdominal aorta with
PBS (pH 7.4) to remove circulating blood, and the right internal jugular
vein was simultaneously severed, allowing free flow of perfusate. 5 ml of
a pre-warmed (50°C) 1% agarose–fluorescent microbead (10%) (0.02-μm
diameter; Invitrogen) mixture was then infused via the 26 G catheter into
the aorta to achieve whole-body microbead perfusion. After cooling the
animals on ice for 10 minutes, the kidneys were harvested and immersed in
neutral buffered formalin for 24 hours at 4°C. 200-μm sections were then
viewed using a confocal microscope at ×5 or ×30 optical zoom (Leica TCS
SL, Leica). Neurolucida software (MBF Bioscience) was used to digitally
reconstruct tissue microvasculature.

Blood SDF-1 measurements in patients

Statistics

A description of the patient cohort and study protocol are provided elsewhere
(54, 55). Briefly, the prospective cohort study consisted of children under the
age of 10, who were recruited to the study upon notification of a stool culture positive for E. coli O157:H7. Participating laboratories were located in
Washington, Oregon, Idaho, Wyoming, Missouri, and Illinois. In addition,
children who reported to the emergency department of the Children’s Hospital and Regional Medical Center in Seattle, Washington, USA, with acute
bloody diarrhea were enrolled at the time of presentation, with appropriate
consent. Data from these samples were included in the study if E. coli O157:
H7 was later confirmed in a stool culture. Each child’s caregiver(s) completed
a standardized questionnaire to identify when diarrhea began. Day 1 of illness was defined as the first day on which diarrhea occurred. Venous blood
samples were obtained at enrollment and as clinically indicated thereafter
until each child either developed and recovered from the HUS or reached
the end of the period of risk for HUS (14 days after the onset of diarrhea)
without further illness. Children were classified as having HUS if hemolytic
anemia (hematocrit below 30%), thrombocytopenia (platelet count less than
150,000/mm3), and renal insufficiency (serum creatinine concentration
exceeding the upper limit of normal for the child’s age) developed (55). Children were classified as having uncomplicated infection if fewer than 3 of the
above criteria were present. Plasma derived from patient blood was collected
using sodium citrate as anticoagulant and stored in aliquots at –70°C until
use. All measurements were performed on blinded samples by sandwich
ELISA (R&D Systems), per the manufacturer’s instructions. Samples were
assigned to 1 out of 3 groups for analysis: those taken from children who
had uncomplicated infection that resolved without subsequent progression
to HUS, those taken on days 2 to 6 of illness from children in whom HUS
later developed, and those from children during HUS on days 1–10 of illness
(55). The first day of diarrhea is defined as day 1 of illness.

Data represent the mean ± SEM of at least 3 independent experiments,
unless otherwise stated. Statistical significance was determined using the
Student’s t test or ANOVA, as appropriate, with Bonferroni, NewmanKeuls, or Dunnett’s post-hoc test. Patient data was analyzed by Wilcoxon
signed-rank test. P < 0.05 was considered statistically significant.

Tissue factor and TFPI protein assays
To collect membrane fractions of HMVECs, cells were washed with cold PBS,
scraped in 100 μl PBS, and sonicated 3 times for 10 seconds using Vibra Cell
VCX400 sonicator (Sonics&Materials Inc.) at 40% maximal power. Samples
were centrifuged at 100,000 g for 60 minutes at 4°C to obtain membrane
proteins in the supernatants. Tissue factor and tissue factor pathway inhibitor activities were determined using Actichrome TF and Actichrome TFPI
Kits (American Diagnotica), per the manufacturer’s instructions.

SDF-1 protein measurements
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